Enhanced radiation damage of tumor vasculature by mTOR inhibitors

Eric T Shinohara1, Carolyn Cao, Ken Niermann

  • 1Department of Radiation Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232-5671, USA.

Oncogene
|June 9, 2005
PubMed

Insights

Radiation therapy activates mTOR signaling in endothelial cells, making them more sensitive to treatment. mTOR inhibitors like rapamycin and RAD001 target tumor vasculature, enhancing radiation

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Radiation therapy activates the PI3K/Akt pathway, influencing tumor vasculature.
  • Mammalian target of rapamycin (mTOR) is a downstream effector of Akt, implicated in cellular response to radiation.
  • Inhibition of PI3K or Akt sensitizes tumor vasculature to radiotherapy, suggesting targeting downstream pathways may enhance treatment efficacy.

Purpose of the Study:

  • To investigate if irradiation activates mTOR signaling in glioma and endothelial cells (ECs).
  • To determine if inhibiting mTOR signaling radiosensitizes tumor vasculature.
  • To evaluate the anti-angiogenic effects of mTOR inhibitors in combination with radiation.

Main Methods:

  • Clonogenic assays to assess radiosensitization of glioma cells and ECs.
  • Western blotting to detect phospho-mTOR and phospho-S6 protein levels in irradiated cells.
  • In vitro endothelial tube formation assays.
  • In vivo studies using glioma xenografts in mice, assessing vascular density and blood flow via Power Weighted Doppler.

Main Results:

  • Irradiation induced mTOR signaling in human umbilical vein endothelial cells (HUVECs) but not GL261 glioma cells.
  • mTOR inhibitors (rapamycin, RAD001) radiosensitized vascular ECs but not glioma cells.
  • Combination of RAD001 with radiation increased apoptosis in ECs and significantly reduced tumor vascular density and blood flow in vivo.
  • Endothelial tube formation was diminished by rapamycin and radiation.

Conclusions:

  • Irradiation activates mTOR signaling specifically in vascular endothelium.
  • mTOR inhibitors enhance the anti-angiogenic effects of radiation by increasing EC apoptosis.
  • Combining mTOR inhibitors with radiation demonstrates potential for improved tumor control through targeted radiosensitization of tumor vasculature.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...